Useful assessment of myocardial viability and dyssynchrony from gated perfusion scintigraphy for better qualification for resynchronization therapy. Part 3

Monika Z. Czała-Ziółkowska\textsuperscript{1}, Jarosław P. Wasilewski\textsuperscript{1}, Jan Glowacki\textsuperscript{2,3}, Zbigniew Wygoda\textsuperscript{4,5}, Mariusz Gąsior\textsuperscript{1}

\textsuperscript{1,3}rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
\textsuperscript{2}Department of Diagnostic Imaging, Silesian Center for Heart Diseases, Zabrze, Poland
\textsuperscript{3}Department of Radiology in Zabrze, Silesian Medical University in Katowice, Poland
\textsuperscript{4}Laboratory of Nuclear Medicine, Silesian Center for Heart Diseases, Zabrze, Poland
\textsuperscript{5}Institute of Nuclear Medicine and Oncological Endocrinology, Center of Oncology, Gliwice, Poland

Abstract

The first part of the review concerning myocardial imaging by single photon emission computed tomography (SPECT) discussed the basic aspects of interpretation of left ventricular perfusion disorders in stress and rest examination. The second part presented the interpretation of gated SPECT imaging in relation to the assessment of systolic and diastolic left ventricular functions. The third part concerns the assessment of myocardial viability and phase analysis from gated SPECT in the qualification of patients with left ventricular systolic dysfunction for cardiac resynchronization therapy.

Key words: GATED-SPECT, myocardial viability, phase analysis.

Introduction

An ECG-gated acquisition (GATED-SPECT) is an integral part of myocardial perfusion scintigraphy. This technique allows assessment of regional contractility and systolic thickening of the left ventricular walls \cite{1, 2}. Phase analysis of left ventricular contraction allows the evaluation of left ventricular contraction, which could be particularly useful in the selection of patients with significantly impaired left ventricular systolic function for CRT device implantation (cardiac resynchronization therapy – CRT).

Although the criteria for resynchronization therapy are restrictive and strictly defined, a significant percentage of patients, especially with ischemic cardiomyopathy, do not improve left ventricular systolic function and increase exercise tolerance \cite{3}. Such patients are referred to as "non-responders". Therefore new methods are being sought to enable proper selection of patients who receive benefit from the expensive treatment method which is CRT implantation.

Quantitative phase analysis of left ventricular dyssynchrony in the resting GATED-SPECT study may be such an auspicious method. It is believed that the greater the dysynchrony of left ventricular contraction, the greater the benefits of CRT therapy that can be expected. In addition, assessment of myocardial viability and determining the location of the scar avoids implantation of the left ventricular lead into the post-infarction scar area, which can contribute to increasing the effectiveness of the method.

Assessment of myocardial viability

Percent segmental radiotracer uptake by the left ventricular muscle in relation to 100\% uptake activity is used to assess myocardial viability in non-gated scintigraphy at rest. When the loss of activity of the radiotracer is less than...
Useful assessment of myocardial viability and dyssynchrony from gated perfusion scintigraphy for better qualification for resynchronization therapy. Part 3

Table I. Segmental viability scales

| Segmental viability                              | Point scale | Loss of activity of the radiotracer |
|--------------------------------------------------|-------------|-------------------------------------|
| Viable                                           | 1           | < 40                                |
| Viable and non-viable muscle within the segment  | 2           | 40–50                               |
| Essentially non-viable                          | 3           | 50–60                               |
| Definitely non-viable                            | 4           | > 60                                |

Figure 1. Assessment of left ventricular myocardial viability in patient A. Lack of viability of the inferior and lateral wall of the left ventricle and preserved viability of the anterior wall, septum and apex in the resting myocardial perfusion SPECT examination with attenuation correction. The polar map divided into 17 segments. The examination was performed in the Laboratory of Nuclear Medicine of the Silesian Center for Heart Diseases in Zabrze (Cedars-Sinai Medical Center software; QPS – Quantified Perfusion SPECT).

Figure 2. Lack of perfusion in patient A. The same patient as in Figure 1. The figure shows the extent of perfusion defects in the resting myocardial perfusion SPECT study with attenuation correction. Polar map division based on arteries. The perfusion deficits correspond to the right coronary artery and the circumflex branch. The examination was performed in the Laboratory of Nuclear Medicine of the Silesian Center for Heart Diseases in Zabrze (Cedars-Sinai Medical Center software; QPS – Quantified Perfusion SPECT).

Figure 3. Point assessment of myocardial viability in patient A. The same patient as in Figures 1, 2. Rest myocardial perfusion SPECT examination with attenuation correction. The polar map divided into 17 segments. According to the point scale, all segments of the inferior and lateral wall were assigned a value of myocardial perfusion defects of 2 or 3 points, which means that there are no clear intermediate features of preserved muscle viability in this area. The assessment of muscle viability should also take into account the result of the left ventricular systolic thickening from GATED-SPECT imaging. The examination was performed in the Laboratory of Nuclear Medicine of the Silesian Center for Heart Diseases in Zabrze (Cedars-Sinai Medical Center software; QPS – Quantified Perfusion SPECT).

40%, the segment is considered as viable. For the partially viable segment, the loss of activity of the radiotracer is 40–50%. For the essentially non-viable segment, the loss of activity of the radiotracer is 50–60%, while for the definitely non-viable segment it is above 60%. A point scale can also be used to evaluate the myocardial viability. In the Cedars-Sinai Medical Center (QPS – Quantified Perfusion SPECT) software, the vital segment is assigned a point value of 1. Two points are assigned to a segment containing both viable and non-viable muscle, three points for a substantially non-viable segment, while four points clearly indicate a lack of muscle viability in the segment (Table I). Wall thickening on GATED-SPECT can also be considered as determination of viability. However, wall thickening is less reliable than the radiotracer uptake [4].

The assessment of left ventricular muscle viability is presented in the example of a patient with ischemic cardiomyopathy and multivessel coronary artery disease. Coronary angiography revealed: significant (≥ 50%) stenosis of the left main coronary artery, unobstructed without significant narrowing of the left anterior descending artery, patent but aneurysm in the proximal segment of circumflex branch, obtuse marginal branches occlusions, and occlusion of the right coronary artery with retrograde filling from the left coronary artery (Figures 1–4).

Assessment of left ventricular mechanical dyssynchrony by phase analysis of gated–SPECT myocardial perfusion imaging

Fourier amplitude-phase analysis of the GATED-SPECT examination allows quantitative assessment of left ven...
tricular dyssynchrony. The distribution of radioactivity for each spatial sampling point of the left ventricle is approximately a sinusoid with a specific phase and amplitude. Figure 5 presents the analysis of left ventricular dyssynchrony in a patient with significantly impaired left ventricular systolic function (left ventricular ejection fraction 17%) in the form of a phase-angle distribution of a polar map and a histogram.

For the measurement of the ventricular dyssynchrony, indexes such as the following are used: PHB (phase histogram bandwidth), i.e. a bandwidth histogram, which includes 95% of the elements of the phase histogram, and PSD (phase standard deviation), i.e. standard deviation of phase distribution, as well as the parameter determined in the software QGS as Entropy for the entire left ventricle or each segment, wall, vessel or coronary vessel group analyzed.

The PHB unit is degrees. The range of normal values for PHB in QGS software is 5° to 39° [5]. The higher the PHB value, the greater is the severity of left ventricular dyssynchrony. The PSD index is the standard deviation of phase distribution. It is also expressed in degrees. The PSD reference values in the QGS software are 0° to 11° [5]. The QGS software also provides an index called Entropy. This parameter determines the percentage of cardiac dyssynchrony. 0% is theoretically assigned to completely synchronized left ventricular contraction, while 100% is assigned to total asynchronous left ventricular contraction. In other words, the higher the Entropy rate, the more chaotic is the contraction of cardiomyocytes. In QGS, the valid Entropy range is 7–41% [5].

The synchronous contraction pattern is reflected by the homogeneous phase angle distribution of the polar map (bull eye); the histogram is narrow and has a large amplitude. When the dyssynchrony is higher, the PHB, PSD and Entropy indexes take higher values (Figure 5). It is worth noting that the PHB and PSD reference values for the QGS software are different than for the Emory Cardiac Toolbox software [6].

It should be noted that the assessment of cardiac dyssynchrony in the myocardial perfusion examination is not only used in the assessment of indications for CRT devices implantation, but is an important independent prognostic indicator of death from cardiovascular causes [7].

Assessment of dyssynchrony of left ventricle in candidates for resynchronization therapy and determination of the optimal left ventricular lead position

Resynchronization therapy reduces mortality and severity of heart failure symptoms in patients with ejection fraction below or equal to 35% and with prolonged QRS complex duration on the resting ECG [8–10]. Unfortunately, it has been shown that about a third of people meeting the criteria for CRT implantation do not respond to resynchronization therapy, which limits the usefulness and cost-effectiveness of this medical procedure [11–13].

There is more and more evidence that the assessment of contraction dyssynchrony from the GATED-SPECT exami-
Useful assessment of myocardial viability and dyssynchrony from gated perfusion scintigraphy for better qualification for resynchronization therapy. Part 3

Figure 6. CRT non-responders phase analysis. An example of a patient without response to CRT. Bottom: segment 6 and 7 phase analysis. PHB, PSD and Entropy for segment 6 were 36°, 10.5° and 45%, respectively, for segment 7: 18°, 4.2° and 26% respectively. Patient with left bundle branch block and left ventricular ejection fraction below 35%. The study was performed in the Laboratory of Nuclear Medicine of the Silesian Center for Heart Diseases in Zabrze (Cedars-Sinai Medical Center software; QGS – Quantified Gated SPECT)

PHB – phase histogram bandwidth, PSD – phase standard deviation.

Fourier analysis of the GATED-SPECT examination may contribute to a better qualification of individuals for CRT therapy. A meta-analysis of 40 patients showed that those who responded favorably to resynchronization therapy had higher PHB and PSD values in the phase analysis from the GATED-SPECT examination compared to patients referred to as “non-responders”.

The optimal cut-off point which indicates the benefit from CRT is 72.5° for PHB and 19.6° for PSD in phase analysis in QGS software [12]. In another study, these parameters were for PHB 112°, PSD 21° and additionally for Entropy 52% respectively (data in QGS software) [13]. The optimal values of dysynchrony parameters in relation to prognosis after CRT implantation are different for Emory Cardiac Toolbox software [14]. An example of phase analysis characteristic for non-responders is presented in Figure 6.

It is believed that patients with ischemic etiology will be less responsive to resynchronization therapy than patients with non-ischemic cardiomyopathy [15]. One study showed that in people with a perfusion defect during rest examination (post-infarction scar) assessed on a summed rest score scale (SRS) as at least 27 points, CRT implantation did not improve left ventricular function, whereas if the SRS was less than 27 points, it was related to benefits after CRT implantation [16].

Zhang et al. suggest that the best left ventricular (LV) lead position is the posterolateral wall, which is in accordance with the European Society of Cardiology (ESC) guidelines [3, 17, 18]. In addition, the ESC recommends that left ventricular lead placement may be targeted at the latest activated area [3]. The largest delay in mechanical contraction can be estimated by the phase analysis of GATED-SPECT examination (Figure 7).

In patients with ischemic heart failure, scarred myocardium regions of the LV lead should be avoided (the loss of activity of the radiotracer above 60% – Table I) [18, 19]. In this case, the left ventricular lead should be positioned at the latest activated areas (Figure 7). But it should be remembered that in patients with ischemic cardiomyopathy, the latest activated areas are the myocardial scar and areas adjacent to the scar [20].

The phase analysis of the SPECT-GATED examination allows the identification of the latest left ventricular activation area, and the perfusion SPECT examination allows the assessment of myocardial viability. Therefore, SPECT examination allows one to identify the most optimal area for implantation of the left ventricular lead, which may improve the benefits of CRT therapy [21].

Conclusions
Fourier analysis of the GATED-SPECT examination may be useful for assessing left ventricular dyssynchrony and selection of patients with significantly impaired left ventricular systolic function who may benefit from resynchronization therapy. In addition, in patients with ischemic cardiomyopathy, phase analysis of the GATED-SPECT study and assessment of myocardial viability may contribute to optimizing the position of the left ventricular lead.

Disclosure
The authors report no conflict of interest.
References

1. Czaja M, Wygoda Z, Duszańska A, et al. Interpreting myocardial perfusion scintigraphy using single-photon emission computed tomography. Part 1. Kardiochir Torakochir Pol 2017; 14: 192-199.
2. Czaja M, Wygoda Z, Duszańska A, et al. Myocardial perfusion scintigraphy – interpretation of gated imaging. Part 2. Kardiochir Torakochir Pol 2018; 15: 49-56.
3. Ponikowski P, Voors AA, Anker SD, et al.; 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The TaskForce for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975.
4. Petretta M, Storto G, Acampa W, et al. Relation between wall thickening on gated perfusion SPECT and functional recovery after coronary revascularization in patients with previous myocardial infarction. Eur J Nucl Med Mol Imaging 2004; 31: 1599-1605.
5. Nakajima K, Matsumoto N, Kasai T, et al. Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med 2016; 30: 188-199.
6. Okuda K, Nakajima K, Matsuo S, et al. Comparison of diagnostic performance of four software packages for phase dysynchrony analysis in gated myocardial perfusion SPECT. EJNMMI Res 2017; 7: 27.
7. Zafrir N, Bental T, Strasberg B, et al. Yield of left ventricular dysynchrony by gated SPECT MPI in patients with heart failure prior to implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator: characteristics and prediction of cardiac outcome. J Nucl Cardiol 2017; 24: 129.
8. Cleland JG, Daubert JC, Erdman E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549.
9. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.
10. Linde X, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Eur Heart J 2013; 34: 2592-2599.
11. Ortizosa N, Perez-Roselló V, Donoso V, et al. Early prediction of cardiac resynchronization therapy response by non-invasive electrocardiogram markers. Med Biol Eng Comput 2018; 56: 611-621.
12. Boogers MM, Van Kriekinge SD, Henneman MM, et al. Quantitative gated SPECT-derived phase analysis on gated myocardial perfusion SPECT detects left ventricular dysynchrony and predicts response to cardiac resynchronization therapy. J Nucl Med 2009; 50: 718-725.
13. Azizian N, Rastgou F, Ghaedian T, et al. LV dyssynchrony assessed with phase analysis on gated myocardial perfusion SPECT can predict response to CRT in patients with end-stage heart failure. Res Cardiovasc Med 2014; 3: e20720.
14. Henneman MM, Chen J, Dibbets-Schneider P, et al. Can LV dyssynchrony as assessed with phase analysis on gated myocardial perfusion SPECT predict response to CRT? J Nucl Med 2007; 48: 1104-1111.
15. Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J 2007; 153: 105-112.
16. Adelstein EC, Tanaka H, Soman P, et al. Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchronization therapy. Eur Heart J 2011; 32: 93-103.
17. Zhang Q, Yip GW, Chen YS, et al. Incremental prognostic value of combining left ventricular lead position and systolic dyssynchrony in predicting long-term survival after cardiac resynchronization therapy. Clin Sci 2009; 117: 397-404.
18. Bose A, Kandala J, Upadhyay GA, et al. Impact of myocardial viability and left ventricular lead location on clinical outcome in cardiac resynchronization therapy recipients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol 2014; 25: 507-513.
19. Bax JJ, Delgado V. Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure. J Nucl Cardiol 2015; 22: 229-245.
20. Lin X, Xu H, Zhao X, Chen J. Sites of latest mechanical activation as assessed by SPECT myocardial perfusion imaging in ischemic and dilated cardiomyopathy patients with LBBB. Eur J Nucl Med Mol Imaging 2014; 41: 1232-1239.
21. Friehling M, Chen J, Saba S, et al. A prospective pilot study to evaluate the relationship between acute change in left ventricular synchrony after cardiac resynchronization therapy and patient outcome using a single-injection gated SPECT protocol. Circ Cardiovasc Imaging 2011; 4: 532-539.